$Histogenics Corporation(OCGN)$A great win for Atmanirbhar Bharat! India’s indigenously developed #COVAXIN shows 81% interim efficacy in Phase 3 trial. We are now one step closer to winning the fight against **. from ICMR巴拉特生物取得了巨大的胜利! 印度本土开发的#COVAXIN在3期试验中显示出81%的中期疗效。 现在,我们距离赢得对抗**的战斗又迈出了一步。
2021-04-06 成本 现价 浮动收益 Histogenics Corporation(OCGN) 0.5338 6.35 +1,091.49% I think Covaxin is very difficult to get fda eua approach to USA before May.The important case is the phase 3 hasn't U.S clinical trials. so I just sell off the last position.